Regeneron Pharmaceuticals, Inc. (REGN)
951.19
-8.22
(-0.86%)
USD |
NASDAQ |
Nov 12, 16:00
953.91
+2.72
(+0.29%)
After-Hours: 20:00
Regeneron Pharmaceuticals Price to Book Value : 2.936 for Nov. 12, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 2.936 |
| November 11, 2026 | 2.961 |
| November 10, 2026 | 2.828 |
| November 09, 2026 | 2.840 |
| November 06, 2026 | 2.792 |
| November 05, 2026 | 2.787 |
| November 04, 2026 | 2.873 |
| November 03, 2026 | 3.004 |
| November 02, 2026 | 2.967 |
| October 30, 2026 | 2.864 |
| October 29, 2026 | 2.527 |
| October 28, 2026 | 2.510 |
| October 27, 2026 | 2.519 |
| October 26, 2026 | 2.493 |
| October 23, 2026 | 2.485 |
| October 22, 2026 | 2.528 |
| October 21, 2026 | 2.487 |
| October 20, 2026 | 2.492 |
| October 19, 2026 | 2.414 |
| October 16, 2026 | 2.441 |
| October 15, 2026 | 2.458 |
| October 14, 2026 | 2.403 |
| October 13, 2026 | 2.325 |
| October 12, 2026 | 2.355 |
| October 09, 2026 | 2.304 |
| Date | Value |
|---|---|
| October 08, 2026 | 2.283 |
| October 07, 2026 | 2.291 |
| October 06, 2026 | 2.280 |
| October 05, 2026 | 2.242 |
| October 02, 2026 | 2.269 |
| October 01, 2026 | 2.268 |
| September 30, 2026 | 2.341 |
| September 29, 2026 | 2.447 |
| September 28, 2026 | 2.453 |
| September 25, 2026 | 2.570 |
| September 24, 2026 | 2.596 |
| September 23, 2026 | 2.614 |
| September 22, 2026 | 2.621 |
| September 21, 2026 | 2.603 |
| September 18, 2026 | 2.559 |
| September 17, 2026 | 2.574 |
| September 16, 2026 | 2.526 |
| September 15, 2026 | 2.524 |
| September 14, 2026 | 2.588 |
| September 11, 2026 | 2.548 |
| September 10, 2026 | 2.586 |
| September 09, 2026 | 2.634 |
| September 08, 2026 | 2.642 |
| September 04, 2026 | 2.699 |
| September 03, 2026 | 2.750 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Gilead Sciences, Inc. | 15.99 |
| AbbVie, Inc. | -- |
| Vertex Pharmaceuticals, Inc. | 6.580 |
| Amgen, Inc. | 17.60 |
| Biogen, Inc. | 1.956 |
Price to Book Value Related Metrics
| PE Ratio | 21.00 |
| PS Ratio | 6.007 |
| PEG Ratio | 2.487 |
| Price to Free Cash Flow | 27.97 |
| Price | 951.19 |
| Earnings Yield | 4.76% |
| Market Cap | 98.35B |
| PEGY Ratio | 2.377 |
| Operating PE Ratio | 19.77 |
| Normalized PE Ratio | 19.48 |